PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Biogen, Ionis ALS drug flops in trials

Biogen and Ionis Pharmaceuticals were hoping to be the first to find a cure for ALS. That dream has now fizzled out with the companies calling it quits after receiving disappointing results from a phase 1 clinical trial.

Study results from a phase 1 study of the drug found that it did not have any real benefits for patients involved in the study. The drug, called BIIB078, did not produce results any different from the drug in the placebo group. In fact, participants who received a 90 mg dose in the study trended toward a greater decline than those in the placebo group, Ionis said. The program will be discontinued as it failed to meet its endpoints.

“While these are not the results we were hoping for, they are clear and will inform future research across our broad pipeline of investigational ALS therapies,” said Toby Ferguson, vice president and head of the neuromuscular development unit at Biogen.

Biogen and Ionis designed BIIB078 based on the current hypothesis that disease mechanisms of ALS are associated with toxicity and repeats within RNA and corresponding dipeptides, short proteins that maintain the pH of cells or act as antioxidants.

The phase 1 study did not support this hypothesis, but Ionis said it will use this information to develop a “deeper understanding” of the disease moving forward.

During the study, adverse events were mostly mild and moderate, with the most common ones being falling, procedural pains, and headaches, according to Ionis. Data from the phase 1 study of BIIB078 will be presented at a future scientific forum, the company said.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026